NCT03043508View on ClinicalTrials.gov

Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)

Active, not recruitingOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

April 10, 2015

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2026

Conditions
Genetic MutationMEN1
Interventions
OTHER

Chart Review

Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.

BEHAVIORAL

Questionnaire

Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03043508 - Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) | Biotech Hunter | Biotech Hunter